-

10:13:54 PM

HOTH Stock News

HOTH - Hoth Therapeutics Inc

10/19/21 12:47 PM

Nasdaq : HOTH

partnership

Hoth Therapeutics Extends Partnership Agreement with REPROCELL

Hoth Therapeutics, Inc . (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants of ulcerative colitis and Crohn's disease tissues will be

RHEA-AI

neutral

10/12/21 10:00 AM

Nasdaq : HOTH

clinical trial

Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence cohort 2 of the Phase 1b clinical trial of BioLexa Lotion for the treatment of mild to

RHEA-AI

neutral

09/21/21 10:05 AM

Nasdaq : HOTH

clinical trial

Hoth Therapeutics Submits to Ethics Committee for Approval to Initiate Patient Cohort 2 in BioLexa Clinical Trial

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that a Safety Review Committee (SRC) has reviewed the safety data from the first cohort of healthy subjects and recommended that the study proceed to dosing

RHEA-AI

neutral

09/08/21 8:02 AM

Nasdaq : HOTH

clinical trial

Hoth Therapeutics Announces Positive Phase 1b Results for Completed First Cohort of Patient Trial of BioLexa

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the completed safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as

RHEA-AI

neutral

08/11/21 9:01 AM

Nasdaq : HOTH

Hoth Therapeutics' mRNA 'Frameshifting' Therapy HT-KIT for Mast Cell Cancers Reduces Size, Spread - Research Published in Molecular Therapy

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today highlights recent findings from North Carolina State University, that its new treatment for mast cell cancers, known as HT-KIT, reduces the number of mast cells by

RHEA-AI

neutral

08/02/21 8:15 AM

Nasdaq : HOTH

clinical trial

Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.The goal of the study is to determine the effects of HT-ALZ on

RHEA-AI

neutral

07/13/21 8:15 AM

Nasdaq : HOTH

Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne

NEW YORK, July 13, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of

RHEA-AI

neutral

06/28/21 8:01 AM

Nasdaq : HOTH

clinical trial

Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

Today, Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, announced the safety results in Cohort 1 of its first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as

RHEA-AI

neutral

06/07/21 2:31 PM

Nasdaq : HOTH

Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZ

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ , a

RHEA-AI

very positive

06/03/21 8:01 AM

Nasdaq : HOTH

clinical trial

Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT Therapeutic

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will share positive results from a preclinical trial during its shareholder presentation, reinforcing the potential of HT-KIT , a new molecular entity

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

HOTH Data:

IndustryMedicinal and Botanical Manufacturing
Websitehoththerapeutics.com
Security nameHoth Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees4
Tags
- Pharmaceuticals: Major
- Health Technology
- Manufacturing
- Medicinal and Botanical Manufacturing

HOTH Description:

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne and other immunological disorders. Hoth has also recently entered into two different agreements to further the development of two different therapeutic prospects to prevent or treat COVID-19.